Todays Report: Today, Rothschild Asset Management Inc. cuts position of Amgen Inc. (AMGN)

Today, Rothschild Asset Management Inc. cuts position of Amgen Inc. (AMGN)

Rothschild Asset Management Inc. lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 213,410 shares of the medical research company’s stock after selling 12,058 shares during the period. Amgen accounts for about 0.6% of Rothschild Asset Management Inc.’s investment portfolio, making the stock its 27th largest position. Rothschild Asset Management Inc.’s holdings in Amgen were worth $35,599,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Amgen by 1.5% in the second quarter. Vanguard Group Inc. now owns 46,679,076 shares of the medical research company’s stock worth $7,102,222,000 after buying an additional 673,247 shares during the last quarter. FMR LLC raised its position in shares of Amgen by 4.0% in the second quarter. FMR LLC now owns 32,386,936 shares of the medical research company’s stock worth $4,927,672,000 after buying an additional 1,259,875 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Amgen by 1.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 20,435,310 shares of the medical research company’s stock worth $3,109,232,000 after buying an additional 271,591 shares during the last quarter. BlackRock Fund Advisors raised its position in shares of Amgen by 1.1% in the second quarter. BlackRock Fund Advisors now owns 12,971,828 shares of the medical research company’s stock worth $1,973,664,000 after buying an additional 138,912 shares during the last quarter. Finally, Nordea Investment Management AB raised its position in shares of Amgen by 37.1% in the second quarter. Nordea Investment Management AB now owns 5,719,168 shares of the medical research company’s stock worth $870,171,000 after buying an additional 1,547,099 shares during the last quarter. Hedge funds and other institutional investors own 79.20% of the company’s stock.

Amgen Inc. (NASDAQ:AMGN) traded up 0.28% during trading on Friday, reaching $145.43. 2,004,017 shares of the company’s stock traded hands. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $176.85. The company has a market cap of $108.19 billion, a PE ratio of 14.56 and a beta of 1.15. The company has a 50 day moving average price of $151.65 and a 200-day moving average price of $160.47.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, October 27th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.79 by $0.23. Amgen had a net margin of 33.63% and a return on equity of 29.27%. The business earned $5.81 billion during the quarter, compared to analysts’ expectations of $5.73 billion. During the same quarter in the prior year, the company posted $2.72 EPS. The business’s revenue for the quarter was up 1.5% on a year-over-year basis. On average, equities research analysts forecast that Amgen Inc. will post $11.56 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 8th. Stockholders of record on Wednesday, November 16th will be paid a $1.00 dividend. The ex-dividend date of this dividend is Monday, November 14th. This represents a $4.00 annualized dividend and a dividend yield of 2.75%. Amgen’s dividend payout ratio (DPR) is 39.92%.

A number of research analysts have recently weighed in on AMGN shares. Leerink Swann restated a “hold” rating on shares of Amgen in a research report on Saturday, September 17th. Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a research report on Monday, August 1st. Goldman Sachs Group Inc. reiterated a “buy” rating and issued a $206.00 price target (up previously from $204.00) on shares of Amgen in a research report on Tuesday, September 27th. Vetr lowered Amgen from a “hold” rating to a “sell” rating and set a $166.35 price target for the company. in a research report on Monday, August 1st. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $190.00 price target on shares of Amgen in a research report on Thursday, September 22nd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $182.04.

Amgen Company Profile

Related posts

Leave a Comment